Fresenius announced today that the Company's Q3 2026 Aide Memoire is now available on the Company's Investor Relations overview section.
As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q3 2026 financial results will be published on November 4, 2026.
Q3 2026 Aide Memoire available
Summary by 6ix
Fresenius has made its Q3 2026 Aide Memoire available in the Investor Relations section of its website. The document summarises information Fresenius has previously communicated or made public to the capital market or otherwise.
Key details
- Fresenius provides an Aide Memoire, a reference summary for capital market participants, each quarter before it publishes its quarterly results.
- Fresenius' financial results for the third quarter of 2026 will be published on November 4, 2026.
6ix wrote this summary from the release below and checked it against the release.
Watch Fresenius SE & Co. KGaA's latest callFresenius Se & Co. KGaA (Xetra:FRE) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Fresenius Se & Co. KGaA (Xetra:FRE) Q2 2026 Earnings CallFresenius SE & Co. KGaA on 6ix
Story so far
Earlier from Fresenius SE & Co. KGaA
- Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by FDA
- Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion
- Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®
- Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
- Fresenius expands European production capacity to enhance healthcare supply chain resilience
Follow Fresenius SE & Co. KGaA into a list and get an email when it puts out news.
Follow Fresenius SE & Co. KGaA